These are preliminary results from Cohort 1 which commenced in December.
It is highly encouraging that even the lowest dose exhibits these results. It demonstrates that MPL is having the intended effect on these two important biomarkers.
We await the neurofilament light chain results from University of Tasmania.
The subsequent cohorts' data will further our knowledge and indicate the Goldilocks dosing regime.
I guess the ultimate proof will be the functionality rating of individual patients. If improvements in quality of life are detected and significant then we truly have a Multi- Billion dollar drug on our hands.
The outcomes of Phase 1 MND trial will inform the expected commencement of a Phase 2 Human Cancer trial later this year. Everything is pointing in the right direction.
Keep the faith!
These are preliminary results from Cohort 1 which commenced in...
-
- There are more pages in this discussion • 342 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.010(5.88%) |
Mkt cap ! $87.55M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 17.0¢ | $36.1K | 210.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 58823 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 154996 | 3 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |